Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published on December 7
The 100% complete response rate in Regeneron's trial represents a potential breakthrough moment that could transform how we treat cancer. Early investors often benefit most from paradigm shifts in healthcare.
The global cancer therapeutics market is worth hundreds of billions and growing rapidly. Companies that crack the code on next-generation treatments could capture enormous value for shareholders.
These aren't speculative bets - they're established leaders and promising specialists handpicked by professional analysts for their cutting-edge immuno-oncology platforms and breakthrough potential.
Regeneron's breakthrough lymphoma therapy with 100% complete response rates validates the immense potential of immuno-oncology. This revolutionary approach engineers the body's immune system to target cancer cells, representing a watershed moment that could transform standard care and create significant investment opportunities across the biotech sector.
This group focuses on companies pioneering next-generation cancer treatments, particularly bispecific antibodies and cell-based therapies. These are cutting-edge medical technologies that work differently from traditional chemotherapy, offering potentially better outcomes with fewer side effects. The field requires substantial research investment but offers tremendous growth potential.
Each company was handpicked by professional analysts for their leadership in immuno-oncology innovation. From Regeneron's breakthrough therapy to Moderna's cancer vaccines and Gilead's CAR T-cell treatments, these firms represent the best-positioned players to capitalise on the next wave of cancer treatment advancement and the capital flowing into this space.
This basket's total market capitalisation is $NaN and is dominated by very large-cap holdings, giving it a generally stable, large-cap profile.
REGN: $75.50B
MRNA: $10.82B
GILD: $150.40B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Earn 6% AER on uninvested cash with daily interest payments.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+3
Here are a few of the assets in this group. Create an account to unlock the full list.
REGENERON PHARMACEUTICALS INC
REGN
Current Price
$820.93
As the company behind the lymphoma therapy breakthrough, Regeneron is a leader in developing bispecific antibodies and other immuno-oncology treatment...
As the company behind the lymphoma therapy breakthrough, Regeneron is a leader in developing bispecific antibodies and other immuno-oncology treatments.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
9 of 13 assets in this group are rated Buy by professional analysts.
